source
- Royalty Pharma pays $125M upfront for royalty stake in AstraZeneca’s ATTR drug cliramitugRoyalty Pharma has entered a deal to acquire a royalty interest in a transthyretin amyloidosis drug being developed by AstraZeneca. The agreement involves an upfront payment of $125 million to Neu…
- AI data emerges as a key hurdle in biopharma partnership dealsAs drug discovery becomes more intricate, the data used to train AI models is turning into a valuable asset in biopharma transactions. Companies are now negotiating not just drug candidates but the…